https://scholars.lib.ntu.edu.tw/handle/123456789/484095
標題: | The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma | 作者: | YU-YUN SHAO Chang Y.-L. Huang C.-Y. CHIH-HUNG HSU ANN-LII CHENG |
公開日期: | 2013 | 出版社: | S. Karger AG | 卷: | 85 | 期: | 5 | 起(迄)頁: | 312-316 | 來源出版物: | Oncology (Switzerland) | 摘要: | Objectives: A germline BIM deletion polymorphism has been proposed to predict a poor treatment efficacy of certain kinase inhibitors. The current study aimed to explore whether the BIM deletion polymorphism predicts the treatment efficacy of sorafenib for advanced hepatocellular carcinoma (HCC). Methods: All patients who were enrolled in clinical trials to receive sorafenib-containing regimens as first-line therapy for advanced HCC and consented to providing peripheral blood samples were included. Polymerase chain reaction followed by gel electrophoresis was used to detect the germline BIM deletion polymorphism. Results: A total of 89 patients were enrolled; 69 (77%) patients had chronic hepatitis B infection, and 18 (20%) had chronic hepatitis C infection. The heterozygous BIM deletion polymorphism was identified in 9 (10%) patients. Patients with and without the BIM deletion polymorphism had similar response rates (11 vs. 6%) and disease control rates (56 vs. 61%). The time to progression, progression-free survival, and overall survival were similar between patients with and without the BIM deletion polymorphism. After adjusting for basic clinicopathologic variables and treatment regimens, the BIM polymorphism still could not predict treatment outcomes. Conclusions: The BIM deletion polymorphism was not associated with the treatment efficacy of sorafenib for advanced HCC. ? 2013 S. Karger AG, Basel. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84889765608&doi=10.1159%2f000356019&partnerID=40&md5=e1009f28576738092beea2db663dcd2d https://scholars.lib.ntu.edu.tw/handle/123456789/484095 |
ISSN: | 0030-2414 | DOI: | 10.1159/000356019 | SDG/關鍵字: | BIM protein; sorafenib; adult; advanced cancer; Article; blood; blood sampling; cancer patient; chronic hepatitis; clinical article; disease control; female; gel electrophoresis; gene deletion; germline mutation; hepatitis B; hepatitis C; human; liver cell carcinoma; male; middle aged; overall survival; polymerase chain reaction; priority journal; progression free survival; treatment outcome; treatment response |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。